Source comparison
How Does Thymosin Alpha-1 Work: Treatment vs. Peptide Comparison
Primary mechanism TLR9 agonist, Th1 polarization, thymic reconstitution Actin-sequestering protein, promotes angiogenesis and wound healing Zinc-dependent thymic hormone, T-cell differentiation cofactor Tα1 is the only thymic peptide with direct TLR9 activatio
This comparison does not assign a generated winner or score.
- Primary mechanism
- TLR9 agonist, Th1 polarization, thymic reconstitution
- Actin-sequestering protein, promotes angiogenesis and wound healing
- Zinc-dependent thymic hormone, T-cell differentiation cofactor
- Tα1 is the only thymic peptide with direct TLR9 activation. Mechanistically distinct from TB-4's regenerative pathway
- Target cell types
- Dendritic cells, plasmacytoid DCs, thymic epithelial cells, CD4+ T-cells
- Endothelial cells, keratinocytes, myocytes, neural progenitors
- Immature thymocytes (CD4−CD8− double-negative stage)
- Tα1 targets antigen-presenting cells; TB-4 targets structural repair; thymulin targets early T-cell development
- Dosing regimen (research)
- 1.6mg subcutaneous injection, twice weekly for 12–48 weeks
- 2–10mg subcutaneous injection, twice weekly for 4–8 weeks
- 50–100mcg intramuscular injection, weekly dosing
- Tα1 requires sustained long-term dosing; TB-4 shows acute-phase effects within weeks
- Clinical evidence base
- 70+ published clinical trials in hepatitis B/C, cancer immunotherapy, sepsis
- Limited human trials; primarily animal wound healing and cardiac models
- Minimal recent clinical data; zinc deficiency states only
- Tα1 has the largest human clinical dataset of any thymic peptide as of 2026
- Reconstitution stability
- Stable 28 days at 2–8°C after reconstitution with bacteriostatic water
- Stable 14 days at 2–8°C; more prone to aggregation than Tα1
- Requires zinc supplementation; unstable without zinc cofactor
- Tα1 offers superior post-reconstitution stability for extended protocols
- Immune specificity
- Enhances cell-mediated (Th1) immunity; minimal effect on humoral (antibody) responses
- No direct immune modulation; indirect via inflammation resolution
- Supports both T-cell and B-cell maturation pathways
- Choose Tα1 for antiviral/anti-tumor studies; thymulin for broad thymic support
- The comparison table demonstrates why conflating thymic peptides creates protocol failures. Researchers expecting TB-500's rapid wound-healing kinetics from Thymosin Alpha-1 will measure the wrong endpoints at the wrong timeframes. Tα1's immune reconstitution timeline spans months, not weeks, because it operates through thymic output and dendritic cell maturation. Neither of which produces acute-phase measurable changes.